Alpha 2.0
Login Register
» Authors » Benien E van Aken

Benien E van Aken

Explore the profile of Benien E van Aken including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 107
Followers 0
Related Specialties
Biochemistry
Hematology
Pathology
Top 10 Co-Authors
Pieter H Reitsma
S Matthijs Boekholdt
Ron J G Peters
Marcel Levi
Harry R Buller
Joost C M Meijers
Nick R Bijsterveld
Hein Fennema
Frits R Rosendaal
Saskia Z H Rittersma
Published In
Br J Haematol
Clin Chem
Circulation
Clin Chem Lab Med
J Histochem Cytochem
Affiliations
Soon will be listed here.
Recent Articles
1.
The effect of homocysteine reduction by B-vitamin supplementation on inflammatory markers
Peeters A, van Aken B, Blom H, Reitsma P, den Heijer M
Clin Chem Lab Med . 2007 Jan; 45(1):54-8. PMID: 17243915
Background: Hyperhomocysteinemia has been associated with vascular disease in many epidemiological studies. However, the pathophysiology is unclear. It is postulated that increased levels of homocysteine induce an inflammatory response in...
2.
Relationship between in vitro lipopolysaccharide-induced cytokine response in whole blood, angiographic in-stent restenosis, and toll-like receptor 4 gene polymorphisms
Rittersma S, Kremer Hovinga J, Koch K, Boekholdt S, van Aken B, Scheepmaker A, et al.
Clin Chem . 2005 Jan; 51(3):516-21. PMID: 15650037
Background: In coronary in-stent restenosis (ISR), a substantial contribution of inflammation is assumed. We evaluated the association between polymorphisms in the Toll-like receptor 4 (TLR4) gene and cytokine response after...
3.
More fibrosis and thrombotic complications but similar expression patterns of markers for coagulation and inflammation in symptomatic plaques from DM2 patients
Sommeijer D, Beganovic A, Schalkwijk C, Ploegmakers H, van der Loos C, van Aken B, et al.
J Histochem Cytochem . 2004 Aug; 52(9):1141-9. PMID: 15314081
Objective: One of the possible pathological mechanisms behind the increased vascular injury in diabetes mellitus type 2 (DM2) is the formation of advanced glycation end products (AGEs). The aim of...
4.
Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers
Bijsterveld N, Vink R, van Aken B, Fennema H, Peters R, Meijers J, et al.
Br J Haematol . 2004 Feb; 124(5):653-8. PMID: 14871253
We investigated whether the anticoagulant effect of idraparinux, a selective long-acting factor Xa inhibitor, could be neutralized by recombinant factor VIIa (rFVIIa) in healthy male volunteers. We performed a randomized,...
5.
Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers
Bijsterveld N, Moons A, Boekholdt S, van Aken B, Fennema H, Peters R, et al.
Circulation . 2002 Nov; 106(20):2550-4. PMID: 12427650
Background: The novel anticoagulant fondaparinux proved to be effective and safe in the postoperative prevention of venous thrombosis. Current phase III trials with this synthetic selective factor Xa inhibitor focus...
6.
Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis
van Aken B, Reitsma P, Rosendaal F
Br J Haematol . 2002 Feb; 116(1):173-7. PMID: 11841414
Elevated plasma levels of interleukin 8 (IL-8) were previously shown to be associated with recurrent venous thrombosis. To assess the risk of venous thrombosis, IL-8 plasma concentrations were measured in...